ctDNA is easily detected in patients with gene mutations, especially with good specificity in EGFR-mutated NSCLC patients, and has been mainly used for molecular analysis to guide clinical drug use and the detection of drug resistance (Wang et al., 2021; Desai et al., 2024). Here, EGFR is linked to non-small cell lung carcinoma.